Cargando…

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy

AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, Affinito, Giuseppina, Berera, Giulia, Marrazzo, Giuseppina, Piscitelli, Raffaele, Carotenuto, Antonio, Petracca, Maria, Lanzillo, Roberta, Triassi, Maria, Brescia Morra, Vincenzo, Palladino, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618479/
https://www.ncbi.nlm.nih.gov/pubmed/35953597
http://dx.doi.org/10.1007/s00415-022-11320-7
_version_ 1784821059256582144
author Moccia, Marcello
Affinito, Giuseppina
Berera, Giulia
Marrazzo, Giuseppina
Piscitelli, Raffaele
Carotenuto, Antonio
Petracca, Maria
Lanzillo, Roberta
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
author_facet Moccia, Marcello
Affinito, Giuseppina
Berera, Giulia
Marrazzo, Giuseppina
Piscitelli, Raffaele
Carotenuto, Antonio
Petracca, Maria
Lanzillo, Roberta
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
author_sort Moccia, Marcello
collection PubMed
description AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS: We included 2495 people with MS from the Campania Region (South Italy) who received first or switch DMT prescription from Jan 2018 to Dec 2020, and with at least 6-month follow-up. We collected hospital discharge records, drug prescriptions, and related costs, and calculated persistence (time from first prescription to discontinuation or switch to other DMT), adherence (proportion of days covered (PDC)), annualized hospitalization rate (AHR) for MS-related hospital admissions, and DMT costs. RESULTS: Ocrelizumab was the most commonly prescribed DMT (n = 399; age = 45.74 ± 10.98 years; females = 224), after dimethyl fumarate (n = 588) and fingolimod (n = 401); 26% patients treated with ocrelizumab were naïve. When compared with ocrelizumab, the risk of discontinuation was higher for other highly active DMTs (HR = 3.78; p = 0.01), and low/medium efficacy DMTs (HR = 7.59; p < 0.01). When compared with ocrelizumab, PDC was similar to other highly active DMTs (Coeff = 0.01; p = 0.31), but higher for low/medium efficacy DMTs (Coeff = 0.09; p < 0.01). When compared with ocrelizumab, AHR was similar to other highly active DMTs (Coeff = 0.01; p = 0.51), and low/medium efficacy DMTs (Coeff = 0.01; p = 0.55). When compared with ocrelizumab, DMT monthly costs were higher for other highly active DMTs (Coeff = 92.30; p < 0.01), but lower for low/medium efficacy DMTs (Coeff = − 1043.61; p < 0.01). DISCUSSION: Ocrelizumab was among the most frequently prescribed DMTs, with 26% prescriptions to treatment-naïve patients, suggesting its relevance in addressing unmet clinical needs (e.g., first approved treatment for primary progressive MS). Ocrelizumab was associated with the highest persistence, confirming its favorable benefit-risk profile. Costs for ocrelizumab were lower than those associated to similarly effective DMTs, in absence of changes in healthcare resource utilization.
format Online
Article
Text
id pubmed-9618479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96184792022-11-01 Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy Moccia, Marcello Affinito, Giuseppina Berera, Giulia Marrazzo, Giuseppina Piscitelli, Raffaele Carotenuto, Antonio Petracca, Maria Lanzillo, Roberta Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele J Neurol Original Communication AIMS: We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and related costs, also in relation to other disease-modifying treatments (DMTs). METHODS: We included 2495 people with MS from the Campania Region (South Italy) who received first or switch DMT prescription from Jan 2018 to Dec 2020, and with at least 6-month follow-up. We collected hospital discharge records, drug prescriptions, and related costs, and calculated persistence (time from first prescription to discontinuation or switch to other DMT), adherence (proportion of days covered (PDC)), annualized hospitalization rate (AHR) for MS-related hospital admissions, and DMT costs. RESULTS: Ocrelizumab was the most commonly prescribed DMT (n = 399; age = 45.74 ± 10.98 years; females = 224), after dimethyl fumarate (n = 588) and fingolimod (n = 401); 26% patients treated with ocrelizumab were naïve. When compared with ocrelizumab, the risk of discontinuation was higher for other highly active DMTs (HR = 3.78; p = 0.01), and low/medium efficacy DMTs (HR = 7.59; p < 0.01). When compared with ocrelizumab, PDC was similar to other highly active DMTs (Coeff = 0.01; p = 0.31), but higher for low/medium efficacy DMTs (Coeff = 0.09; p < 0.01). When compared with ocrelizumab, AHR was similar to other highly active DMTs (Coeff = 0.01; p = 0.51), and low/medium efficacy DMTs (Coeff = 0.01; p = 0.55). When compared with ocrelizumab, DMT monthly costs were higher for other highly active DMTs (Coeff = 92.30; p < 0.01), but lower for low/medium efficacy DMTs (Coeff = − 1043.61; p < 0.01). DISCUSSION: Ocrelizumab was among the most frequently prescribed DMTs, with 26% prescriptions to treatment-naïve patients, suggesting its relevance in addressing unmet clinical needs (e.g., first approved treatment for primary progressive MS). Ocrelizumab was associated with the highest persistence, confirming its favorable benefit-risk profile. Costs for ocrelizumab were lower than those associated to similarly effective DMTs, in absence of changes in healthcare resource utilization. Springer Berlin Heidelberg 2022-08-11 2022 /pmc/articles/PMC9618479/ /pubmed/35953597 http://dx.doi.org/10.1007/s00415-022-11320-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Moccia, Marcello
Affinito, Giuseppina
Berera, Giulia
Marrazzo, Giuseppina
Piscitelli, Raffaele
Carotenuto, Antonio
Petracca, Maria
Lanzillo, Roberta
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title_full Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title_fullStr Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title_full_unstemmed Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title_short Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
title_sort persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the campania region of italy
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618479/
https://www.ncbi.nlm.nih.gov/pubmed/35953597
http://dx.doi.org/10.1007/s00415-022-11320-7
work_keys_str_mv AT mocciamarcello persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT affinitogiuseppina persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT bereragiulia persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT marrazzogiuseppina persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT piscitelliraffaele persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT carotenutoantonio persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT petraccamaria persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT lanzilloroberta persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT triassimaria persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT bresciamorravincenzo persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly
AT palladinoraffaele persistenceadherencehealthcareresourceutilizationandcostsforocrelizumabintherealworldofthecampaniaregionofitaly